Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 10.3389/fphar.2016.00165 Pharmacology Erratum Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach Frontiers Production Office * Frontiers Production Office, Frontiers Lausanne, Switzerland

Approved by: Pharmacology Editorial Office, Frontiers, Switzerland

*Correspondence: Frontiers Production Office production.office@frontiersin.org

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

 06 06 2016 2016 7 165 01 06 2016 01 06 2016 Copyright © 2016 Frontiers Production Office. 2016 Frontiers Production Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 An erratum on Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach by Platania, C. B. M., Di Paola, L., Leggio, G. M, Romano, G. L., Drago, F., Salomone, S., et al. (2015) Front. Pharmacol. 6:248. doi: 10.3389/fphar.2015.00248 ranibizumab bevacizumab aflibercept diabetic retinopathy molecular dynamics

Reason for Erratum:

Due to a typesetting error, the article was published with incorrect values in Table 4. The publisher apologizes for this error and the correct version of Table 4 appears below. This error does not change the scientific conclusions of the article in any way.

MM-PBSA results compared to experimental binding parameters.

Complex Binding parameters MM-PBSA energy terms (KJ/mol)
Kon/105 (M−1 s−1) Koff/10−5 (s−1) KD (pM) ΔEbinding ΔEVdW ΔEelectrostatic ΔGPolar ΔGApolar
Ranibizumab/VEGFA 1.60 0.73 46 −760 ± 40 −418 ± 5 −160 ± 20 410 ± 30 −592 ± 7
Fab-bevacizumab/VEGFA 5.30 3.10 58 −807 ± 30 −362 ± 10 −252 ± 20 343 ± 30 −536 ± 7
VEGFR1d2_R2d3/VEGFA 410 2.01 0.49 −1440 ± 90 −307 ± 50 −1433 ± 100 1050 ± 100 −750 ± 40

Kinetic and binding parameters are from Papadopoulos et al. (2012).

 References Papadopoulos N. Martin J. Ruan Q. Rafique A. Rosconi M. P. Shi E. . (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15, 171–185. 10.1007/s10456-011-9249-622302382